Scrip Asia 100 - GSK takes the flexible approach to Asian growth
This article was originally published in Scrip
GlaxoSmithKline's approach to growing its business across the Asia-Pacific region recognises the need for distinct strategies tailored to each national market. This may involve a blend of price cuts, regional co-promotion partnerships and targeted M&A deals. The company also realises that innovation can come from any source, Marc Dunoyer tells Ian Haydock in an exclusive one-on-one interview.
You may also be interested in...
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.